Baird Medical Shines at 2025 Microcap Conference: Driving Growth Through Technological Innovation and Strategic Collaborations

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD), a leader in microwave ablation technology, participated in the 2025 Microcap Conference at the Borgata Hotel in Atlantic City. The event, which attracted over 750 institutional investors and industry experts, served as a platform for the company to showcase its minimally invasive microwave ablation technology and discuss its recent FDA 510(k) clearance for the U.S. market.

During the conference, Baird Medical's leadership team conducted one-on-one meetings with investors to outline U.S. market penetration strategies and engaged in discussions about potential mergers and acquisitions. Chairwoman Haimei Wu emphasized the conference's role in connecting with global investors and identifying collaboration opportunities. The company plans to leverage these insights to advance its global expansion while continuing investments in research and development.

Positive

• Recent FDA 510(k) clearance obtained for U.S. market entry
• Active discussions with potential M&A partners for strategic growth
• Strong positioning in microwave ablation technology sector

Negative

• None.

News Market Reaction

+4.30%

1 alert

+4.30% News Effect

On the day this news was published, BDMD gained 4.30%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in microwave ablation (MWA) technology, today announced its successful participation in the 2025 Microcap Conference, held at the Borgata Hotel in Atlantic City, New Jersey. The Company showcased its innovative solutions and engaged in high-level discussions with investors and industry leaders during the 3-day event.

As the largest independent microcap conference in the U.S., the 2025 Microcap Conference brought together over 750 institutional investors, venture capital representatives, and industry experts from around the world. This prestigious event provided Baird Medical with an exceptional platform to highlight its technological advancements and explore strategic opportunities.

At the conference, Baird Medical demonstrated its cutting-edge minimally invasive microwave ablation technology, drawing significant attention from attendees and underscoring the Company's leadership in research and development. Additionally, the Company shared its global expansion strategy following the recent FDA 510(k) clearance for the U.S. market.

During the event, Baird Medical's leadership team held numerous one-on-one meetings with investors, detailing the Company's growth plans for the U.S. market, including market penetration strategies and product promotion initiatives. The team also engaged in extensive discussions with several industry players regarding potential mergers and acquisitions. These conversations focused on resource integration, technological synergies, and market collaboration, aiming to identify strategic opportunities that could drive mutual growth and advance the microwave ablation industry.

"The Microcap Conference provided us with a valuable opportunity to connect with global investors and industry partners," said Haimei Wu, Chairwoman of Baird Medical. "We not only showcased our technological expertise but also gained clarity on future collaboration opportunities. We look forward to accelerating our global market expansion and achieving efficient resource integration through strategic mergers and acquisitions."

Moving forward, Baird Medical plans to leverage the insights and partnerships gained from the conference to further its mission of improving patient outcomes worldwide through innovative technologies. The Company will continue to invest in research and development to enhance product quality and performance while actively exploring merger and acquisition opportunities to consolidate its global leadership in the microwave ablation field. By integrating complementary resources, Baird Medical aims to deliver superior medical solutions to patients around the world.

About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-shines-at-2025-microcap-conference-driving-growth-through-technological-innovation-and-strategic-collaborations-302363962.html

SOURCE BDMD

FAQ

What was the significance of Baird Medical's (BDMD) participation in the 2025 Microcap Conference?

The conference provided BDMD with a platform to showcase its microwave ablation technology, connect with over 750 institutional investors, and explore strategic M&A opportunities while presenting its U.S. market expansion plans following FDA 510(k) clearance.

What recent regulatory approval did Baird Medical (BDMD) receive for the U.S. market?

Baird Medical received FDA 510(k) clearance for its microwave ablation technology, enabling market entry into the United States.

What strategic opportunities is Baird Medical (BDMD) pursuing after the 2025 Microcap Conference?

BDMD is actively exploring merger and acquisition opportunities, focusing on resource integration, technological synergies, and market collaboration to drive growth in the microwave ablation industry.

How does Baird Medical (BDMD) plan to expand in the U.S. market?

BDMD plans to implement market penetration strategies and product promotion initiatives, while leveraging insights gained from the conference to enhance their presence in the U.S. market.